Pre-made Lambrolizumab benchmark antibody ( Whole mAb, anti-PDCD1/PD-1 therapeutic antibody, Anti-CD279/PD1/SLEB2/hSLE1 Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-292

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-292 Category Tag

Product Details

Pre-Made Lambrolizumab biosimilar, Whole mAb, Anti-PDCD1/PD-1 Antibody: Anti-CD279/PD1/SLEB2/hSLE1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Pembrolizumab, sold under the brand name Keytruda, is a humanized antibody used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, and stomach cancer.[5] It is given by slow injection into a vein.

Products Name (INN Index)

Pre-Made Lambrolizumab biosimilar, Whole mAb, Anti-PDCD1/PD-1 Antibody: Anti-CD279/PD1/SLEB2/hSLE1 therapeutic antibody

INN Name

Lambrolizumab

Target

PDCD1

Format

Whole mAb

Derivation

NA

Species Reactivity

Human

CH1 Isotype

IgG4

VD LC

Kappa

Highest_Clin_Trial (Jan '20)

Approved

Est. Status

Active

100% SI Structure

5dk3:GF:BA/5ggs:CD:AB/5b8c:BA:HG:KJ:ED/5jxe:GF:DC

99% SI Structure

None

95-98% SI Structure

None

Year Proposed

2013

Companies

Aduro BioTech,AIO Studien gGmbH,Amgen,Augusta University,Bayer,BerGenBio,Big Ten Cancer Research Consortium,BioLineRx,Canadian Cancer Trials Group,Celgene Corporation,Columbia University,Dana-Farber

Conditions Approved

Cervical cancer,Colorectal cancer,Diffuse large B cell lymphoma,Gastric cancer,Head and neck cancer,Hodgkin's disease,Liver cancer,Malignant melanoma,Non-small cell lung cancer,Pancreatic cancer,Soli

Conditions Active

Small cell lung cancer,Fallopian tube cancer,Gastrointestinal cancer,Mesothelioma,Multiple myeloma,Nasopharyngeal cancer,Ovarian cancer,Peritoneal cancer,Prostate cancer,Squamous cell cancer,Acute my

Conditions Discontinued

NA

Development Tech

NA

Previous Name

pembrolizumab

Gm Offical Target Name

PDCD1

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide